Royal Philips has acquired US-based sensor technologies developer Xhale Assurance as part of its strategy to expand its monitoring & analytics business.
Financial details of the transaction have not been disclosed.
Xhale Assurance developed a disposable pulse oximetry sensor to measure and transmit patients’ heart rate and blood oxygenation data in low perfusion conditions.
Xhale sensor is said to accurately measure at lower oxygen saturation levels, which is considered critical for patients who have had a heart attack or hypoxic event.
The sensor also delivers early warning signals to caregivers in case of impending adverse events.
Philips expects Xhale’s technology to bolster its oxygen saturation monitoring solutions portfolio.
Royal Philips Monitoring & Analytics business leader Felix Baader said: “Xhale Assurance’s nasal alar sensor offers exceptional clinical capabilities and strengthens our patient monitoring offering with a next-generation pulse oximetry sensor technology.
“The sensor technology also offers opportunities to develop measurements of further physiologic parameters.”
Baader added that the sensor will help the company in providing solutions that will improve patient safety and caregiver efficiency, as well as support clinical workflow.
Philips patient monitoring portfolio is said to address any type of acuity level and care setting in hospitals and health systems. These solutions are used to monitor more than 275 million patients a year.
The portfolio of patient monitoring solutions includes bedside and wearable patient monitors, along with consumables such as connected wearable biosensors.
Philips also offers clinical decision support tools and mobile applications to capture clinical information in real-time at the patient’s bedside.
